Clopidogrel: Price, Dosage & Where to Buy

Clopidogrel is an antiplatelet medicine in the P2Y12 platelet inhibitor class, used to reduce the risk of heart attack and stroke in people with cardiovascular disease. It helps stop platelets in the blood from sticking together and forming clots, and it requires a prescription in the United Kingdom.

Clopidogrel is used to reduce the risk of heart attack and stroke in people with acute coronary syndrome. This includes unstable angina and heart attacks classified as either non-ST-elevation or ST-elevation myocardial infarction. For these conditions, the label specifies use alongside aspirin.

It is also used to reduce the risk of heart attack and stroke in people who have recently had a heart attack or stroke, or who have established peripheral arterial disease. Peripheral arterial disease affects the arteries carrying blood to areas such as the legs.

Clopidogrel reduces the ability of platelets to stick together. Platelets are small components of blood that help form clots; their activity can also contribute to clots within blood vessels. Clopidogrel blocks a platelet signalling pathway called P2Y12, reducing this clot-forming activity.

The medicine must first be converted into an active substance by liver enzymes, mainly CYP2C19. Genetic differences or medicines that affect this enzyme can change how well clopidogrel works. Its effect on an affected platelet lasts for that platelet's lifetime.

The label lists oral tablets containing 75 mg or 300 mg. The label lists a single 300 mg oral loading dose for acute coronary syndrome when an antiplatelet effect is needed within hours, followed by 75 mg once daily. Starting treatment without a loading dose delays the establishment of the antiplatelet effect by several days.

The label lists 75 mg once daily orally, without a loading dose, for people with a recent heart attack, recent stroke or established peripheral arterial disease. For acute coronary syndrome, the label specifies treatment alongside aspirin. No dosage adjustment is necessary in elderly patients or in patients with hepatic impairment, according to the label.

Experience in people with moderate or severe renal impairment is limited. These are label dosing facts, rather than an individual treatment plan.

A missed dose can interrupt the prescribed treatment schedule. General pharmacy guidance is to resume the usual schedule if the next dose is nearly due, rather than doubling a dose to make up for one missed.

A pharmacist can advise if the timing is uncertain. Avoid stopping clopidogrel independently, because premature discontinuation increases cardiovascular risk.

Available pregnancy reports have not found an association between clopidogrel and major birth defects or miscarriage. Use during labour or delivery increases maternal bleeding risk, and spinal or epidural procedures require careful medical planning. There are no data on clopidogrel in human milk or its effects on milk production.

No adverse effects in breastfed infants were observed in a small number of reported cases. Breastfeeding benefits should be weighed against the mother's treatment needs and potential infant risks.

The label specifies storage at 25° C, with excursions permitted to 15° to 30° C. Keep the medicine out of the sight and reach of children and follow the storage directions on its packaging.